Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be male or female between the ages of 18 and 70~* Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnosis of bipolar disorder (type I, II, or NOS)~* Currently depressed as confirmed by the MINI-Plus at the screening visit~* Currently receiving treatment with an anti-manic drug~* Meets criteria for metabolic syndrome or insulin resistance~Exclusion Criteria:~* Pregnancy or breast feeding~* Unstable or inadequately treated medical illness as judged by the investigator~* Severe personality disorder~* Serious suicidal risk~* Known history of intolerance or hypersensitivity to pioglitazone~* Treatment with pioglitazone in the 3 months prior to randomization~* Dependence on alcohol or drugs (other than nicotine) in the 3 months prior to study entry~* Currently taking an antidiabetic/glucose-lowering agent.~* Diagnosed with dementia~* Acute Mania as defined by a Young Mania Rating Scale (YMRS) score \> 15~* Diagnosed with heart failure~* Transaminase elevation \>2.5 times the upper limit of normal~* Presence of renal impairment (eg. creatinine \> 1.5)~* Fasting blood glucose \>150 mg/dL~* Hb A1c \> 7.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).